Respiratory syncytial virus prophylaxis reduced the risk of recurrent wheezing for children who were born prematurely but had no family history of atopy or asthma, researchers said. The study found children ages 2 to 5 who did not have a family history of asthma were 68% less likely to get recurrent wheezing when given palivizumab compared with untreated children.

Related Summaries